Cited 0 times in
S78: Dupilumab reduces risk of severe exacerbations and improves FEV1 regardless of baseline disease severity in patients with uncontrolled, moderate-to-severe asthma: data from the phase 3 LIBERTY ASTHMA QUEST study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pavord, I | - |
dc.contributor.author | Papi, A | - |
dc.contributor.author | Wenzel, S | - |
dc.contributor.author | Park, HS | - |
dc.contributor.author | Rice, M | - |
dc.contributor.author | Staudinger, H | - |
dc.contributor.author | Maroni, J | - |
dc.contributor.author | Rowe, P | - |
dc.contributor.author | Rout, R | - |
dc.contributor.author | Amin, N | - |
dc.contributor.author | Akinlade, B | - |
dc.contributor.author | Graham, NMH | - |
dc.contributor.author | Teper, A | - |
dc.date.accessioned | 2019-12-10T06:53:42Z | - |
dc.date.available | 2019-12-10T06:53:42Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 0040-6376 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/17804 | - |
dc.language.iso | en | - |
dc.title | S78: Dupilumab reduces risk of severe exacerbations and improves FEV1 regardless of baseline disease severity in patients with uncontrolled, moderate-to-severe asthma: data from the phase 3 LIBERTY ASTHMA QUEST study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 박, 해심 | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1136/thorax-2018-212555.84 | - |
dc.citation.title | Thorax | - |
dc.citation.volume | 73 | - |
dc.citation.number | S4 | - |
dc.citation.date | 2018 | - |
dc.citation.startPage | A48 | - |
dc.citation.endPage | A48 | - |
dc.identifier.bibliographicCitation | Thorax, 73(S4). : A48-A48, 2018 | - |
dc.embargo.liftdate | 9999-12-31 | - |
dc.embargo.terms | 9999-12-31 | - |
dc.identifier.eissn | 1468-3296 | - |
dc.relation.journalid | J000406376 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.